简介 联系方式 相互作用: 118 620
根据名称进行药物检索

Ketoprofen Capsules与胃肠道毒性

Ketoprofen Capsules与胃肠道毒性安全配伍检测的结果。

检测结果:
Ketoprofen Capsules <> 胃肠道毒性
现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

非甾体抗炎药(非甾体抗炎药)可能会导致胃肠粘膜的损坏风险的出现是相关的两个剂量和持续时间的治疗。 严重的GI的毒性，例如出血溃疡和穿孔可以开发在任何时间,有或没有的警示症状，并发生在大约1%的患者接受治疗的3至6个月和2%至4%的患者接受治疗一年。 这些趋势继续持续时间较长的使用，尽管短期的治疗并不是没有风险。 虽然代理，有选择地抑制环氧化酶-2(即，二氧化碳-2抑制剂)是一般认为是相关的减少风险的GI毒性相比于传统药物，他们没有被证明有风险。 此外，有证据表明，二氧化碳-2抑制剂可能会延误治疗胃溃疡的，并有可能以相同的程度，因为传统的非甾体抗炎药. 因此，治疗的所有药物，包括二氧化碳-2抑制剂，应该规定谨慎的患者的历史的胃溃疡病和/或肠胃道出血。 患有这样的历史使用药物有一大于10倍的风险增加对发展中GI流血相比，患者无论这些风险因素。 小心外，还建议如果非甾体抗炎药规定对患者有其他危险因素，如口头皮质类固醇或抗凝血剂使用，使用酒精、吸烟、老年人和穷人的一般健康状况。 特别警惕的是必要时治疗老年人(即年龄在60岁或以上)和/或体弱者，因为他们往往更容易受到胃肠毒性的这些药物，似乎容忍溃疡出血不太好，比较年轻、健康的个人。 只要有可能，特别是如果长时间使用的是预期的治疗与非溃疡的药剂应该尝试的第一个。 如果非甾体抗炎药的使用，患者应处理的最低有效剂量为最短期限的可能和预防性治疗剂的细胞保护(例如，米索前列醇)，组胺H2-受体拮抗剂或一枚质子泵抑制剂应当给予必要的。 病人应当建议避免或尽量减少酒精消费在非甾体疗法。 三个或更多的酒精饮料，每天在非甾体使用可能增加的风险胃肠溃疡出血. 病人也应该被告知要立即寻求医疗注意，如果他们遇到的症状可能表示严重的胃肠溃疡出血或如上腹部疼痛、消化不良、梅琳娜，并且吐血.

来源
  • Lanza FL, Nelson RS, Royer GL "Effects of ibuprofen, tolmetin and placebo on the gastric mucosa of aspirin-sensitive volunteers." Am J Gastroenterol 72 (1979): 528-34
  • Scott B "Bleeding massive gastric ulcer on diflunisal (Dolobid) ." Br Med J 1 (1979): 489
  • Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5
  • Carson J, Notis WM, Orris ES "Colonic ulceration and bleeding during diclofenac therapy ." N Engl J Med 323 (1990): 135
  • "Product Information. Mobic (meloxicam)" Boehringer-Ingelheim, Ridgefield, CT.
  • Oren R, Ligumsky M "Indomethacin-induced colonic ulceration and bleeding." Ann Pharmacother 28 (1994): 883-5
  • van Eeden A, Schotborgh RH, Tytgat GN "An endoscopic evaluation of the effects of etodolac and diclofenac on the gastric and duodenal mucosa." Clin Ther 12 (1990): 496-502
  • Taha AS, McLaughlin S, Holland PJ, Kelly RW, Sturrock RD, Russell RI "Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis." Ann Rheum Dis 49 (1990): 354-8
  • Simon LS, Weaver AL, Graham DY, et al. "Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid artthritis: a randomised controlled trial." JAMA 282 (1999): 1921-8
  • Armstrong CP, Blower AL "Ulcerogenicity of piroxicam: an analysis of spontaneously reported data." Br Med J (Clin Res Ed) 294 (1987): 772
  • Levine MS, Rothstein RD, Laufer I "Giant esophageal ulcer due to clinoril." Am J Roentgenol 156 (1991): 955-6
  • Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJS, Bjarnason I "The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis." Scand J Gastroenterol 30 (1995): 289-99
  • Fuller DK, Kalekas PJ "Ketorolac and gastrointestinal ulceration." Ann Pharmacother 27 (1993): 978-9
  • Santucci L, Patoia L, Fiorucci S, Farroni F, Favero D, Morelli A "Oesophageal lesions during treatment with piroxicam." BMJ 300 (1990): 1018
  • Taha AS, Sturrock RD, Russell RI "Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to helicobacter pylori." Gut 36 (1995): 334-6
  • Allen B, Edwards R "A safety profile of controlled release naproxen tablets." N Z Med J 102 (1989): 310-2
  • Wilcox GM, Porensky RS "Acute colitis associated with etodolac." J Clin Gastroenterol 25 (1997): 367-8
  • O'Brien WM "Long-term efficacy and safety of tolmetin sodium in treatment of geriatric patients with rheumatoid arthritis and osteoarthritis: a retrospective study." J Clin Pharmacol 23 (1983): 309-23
  • Bataille C, Soumagne D, Loly J, Brassinne A "Esophageal ulceration due to indomethacin." Digestion 24 (1982): 66-8
  • "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • Roth SH "Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy." Am J Med 83 (1987): 25-30
  • Lanza FL, Royer GL Jr, Nelson RS, et al "A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa." Am J Gastroenterol 75 (1981): 17-21
  • Deakin M "Small bowel perforation associated with an excessive dose of slow release diclofenac sodium." BMJ 297 (1988): 488-9
  • Lussier A, LeBel E "Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone." Am J Med 83 (1987): 15-8
  • Mehta S, Dasarathy S, Tandon RK, Mathur M, Malaviya AN "A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis." Am J Gastroenterol 87 (1992): 996-1000
  • Thompson MR "Indomethacin and perforated duodenal ulcer." Br Med J 02/16/80 (1980): 448
  • Bergmann JF, Chassany O, Geneve J, Abiteboul M, Caulin C, Segrestaa JM "Endoscopic evaluation of the effect of ketoprofen, ibuprofen and aspirin on the gastroduodenal mucosa." Eur J Clin Pharmacol 42 (1992): 685-8
  • Whitcomb DC, Martin SP, Trellis DR, Evans BA, Becich MJ "'Diaphragmlike' stricture and ulcer of the colon during diclofenac treatment." Arch Intern Med 152 (1992): 2341-3
  • "Product Information. Vioxx (rofecoxib)." Merck & Co, Inc, West Point, PA.
  • Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1
  • Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS "Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison." Lancet 354 (1999): 2106-11
  • Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94
  • Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W "Effectiveness of National Provider Prescription of PPI Gastroprotection Among Elderly NSAID Users." Am J Gastroenterol 103 (2008): 323-32
  • "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Collins AJ, Davies J, Dixon ASJ "A prospective endoscopic study of the effect of orudis and oruvail on the upper gastrointestinal tract, in patients with osteoarthritis." Br J Rheumatol 27 (1988): 106-9
  • Schattenkirchner M "An updated safety profile of etodolac in several thousand patients." Eur J Rheumatol Inflamm 10 (1990): 56-65
  • Baert F, Hart J, Blackstone MO "A case of diclofenac-induced colitis with focal granulomatous change." Am J Gastroenterol 90 (1995): 1871-3
  • "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc, Palo Alto, CA.
  • Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8
  • "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical, Raritan, NJ.
  • "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals, East Hanover, NJ.
  • "Product Information. Feldene (piroxicam)." Pfizer US Pharmaceuticals, New York, NY.
  • Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg B, Ehrich EW "The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis." Clin Ther 21 (1999): 1688-702
  • Lanza F, Rack MF, Lynn M, Wolf J, Sanda M "An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa." J Rheumatol 14 (1987): 338-41
  • Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6
  • Ecker GA, Karsh J "Naproxen induced ulcerative esophagitis." J Rheumatol 19 (1992): 646-7
  • Greb WH, von Schrader HW, Cerlek S, Dominis M, Hauptmann E, Zenic N "Endoscopic studies of nabumetone in patients with rheumatoid arthritis. A comparative endoscopic and histologic evaluation." Am J Med 83 (1987): 19-24
  • "Product Information. Dolobid (diflunisal)." Merck & Co, Inc, West Point, PA.
  • Maliekal J, Elboim CM "Gastrointestinal complications associated with intramuscular ketorolac tromethamine therapy in the elderly." Ann Pharmacother 29 (1995): 698-701
  • Mason AM "Bleeding massive gastric ulcer on diflunisal (Dolobid) ." Br Med J 1 (1979): 888
  • Clements D, Williams GT, Rhodes J "Colitis associated with ibuprofen." Br Med J 301 (1990): 987
  • Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J "A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis." Gastroenterology 117 (1999): 776-83
  • Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6
  • Kwo PY, Tremaine WJ "Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature." Mayo Clin Proc 70 (1995): 55-61
  • Bernhard GC "Worldwide safety experience with nabumetone." J Rheumatol 19 (1992): 48-57
  • "Product Information. Relafen (nabumetone)." SmithKline Beecham, Philadelphia, PA.
  • Brooks CD, Linet OI, Schellenberg D, Turner LF, Defesche CL, Teoh KW, Johnson JH, Assenzo JR "Clinical safety of flurbiprofen." J Clin Pharmacol 30 (1990): 342-51
  • Wiedrick JE, Friesen EG, Garton AM, Otten NH "Upper gastrointestinal bleeding associated with oral ketorolac therapy." Ann Pharmacother 28 (1994): 1109
  • Fok KH, George PJ, Vicary FR "Peptic ulcers induced by piroxicam." Br Med J (Clin Res Ed) 290 (1985): 117
  • "Product Information. Clinoril (sulindac)." Merck & Co, Inc, West Point, PA.
  • Peskar BM, Maricic N, Gretzera B, Schuligoi R, Schmassmann A "Role of cyclooxygenase-2 in gastric mucosal defense." Life Sci 69 (2001): 2993-3003
  • Heynen G "Toleration and safety of piroxicam." Eur J Rheumatol Inflamm 8 (1987): 86-93
  • Goldenberg MM "Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis." Clin Ther 21 (1999): 1497-513
  • Strom BL, Berlin JA, Kinman JL "Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: a postmarketing surveillance study." JAMA 275 (1996): 376-82
  • Feldman M, McMahon AT "Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?." Ann Intern Med 132 (2000): 134-43
  • Witham R "Voltaren (diclofenac sodium)-induced ileocolitis ." Am J Gastroenterol 86 (1991): 246-7
  • Estes LL, Fuhs DW, Heaton AH, Butwinick CS "Gastric ulcer perforation associated with the use of injectable ketorolac." Ann Pharmacother 27 (1993): 42-3
  • "Product Information. Nalfon (fenoprofen)." Xspire Pharma, Ridgeland, MS.
  • Bombardier C, Laine L, Reicin A, et al. "Comparison of upper gastrointestinal toxicity of refecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group." N Engl J Med 343 (2000): 1520-8
  • "Product Information. Daypro (oxaprozin)." Searle, Skokie, IL.
  • Roth SH "Naproxen: antirheumatic efficacy and safety in patients with pre-existing gastrointestinal disease." Semin Arthritis Rheum 17 (1988): 36-9
  • Quigley EMM, Donovan JP, Livingston WC "Ketorolac-related giant gastric ulcers." Am J Gastroenterol 89 (1994): 631-2
  • Catalano MA "Worldwide safety experience with diclofenac." Am J Med 80 (1986): 81-7
  • "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn, Kalamazoo, MI.
  • Wolfe MM, Lichtenstein DR, Singh G "Gastrointestinal toxicity of nonsteroiddal antiinflammatory drugs." N Engl J Med 340 (1999): 1888-99
  • "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • "Product Information. Bextra (valdecoxib)." Pharmacia Corporation, Peapack, NJ.
  • Silverstein FE, Faich G, Goldstein JL, et al. "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthtitis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial." JAMA 284 (2000): 1247-55
  • Wolfe PA, Polhamus CD, Kubik C, Robinson AB, Clement DJ "Giant duodenal ulcers associated with the postoperative use of ketorolac: report of three cases." Am J Gastroenterol 89 (1994): 1110-1
  • Geczy M, Peltier L, Wolbach R "Naproxen tolerability in the elderly: a summary report." J Rheumatol 14 (1987): 348-54
  • Venturatos SG, Hines C Jr, Blalock JB "Ulceration of the small intestine in a patient with celiac disease." South Med J 77 (1984): 520-2
  • Halter F, Tarnawski AS, Schmassmann A, Peskar BM "Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives." Gut 49 (2001): 443-53
  • Bianchi Porro G, Caruso I, Petrillo M, Montrone F, Ardizzone S "A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients." J Intern Med 229 (1991): 5-8
  • Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8
  • Willkens RF "Worldwide clinical safety experience with diclofenac." Semin Arthritis Rheum 2 Suppl 1 (1985): 105-10
  • Fitzgerald GA, Patrono C "The coxibs, selective inhibitors of cyclooxsygenase-2." N Engl J Med 345 (2001): 433-42
  • Khoury MI "Ulcerative proctitis in juvenile systemic lupus erythematosus after ibuprofen treatment." J Rheumatol 16 (1989): 217-8
  • Voss GD, Schweitzer P "GI bleeding associated with nabumetone." Am J Hosp Pharm 51 (1994): 2506-8
  • Lanza FL, Codispoti JR, Nelson EB "An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen." Am J Gastroenterol 93 (1998): 1051-4
  • Siegel MA, Balciunas BA "Medication can induce severe ulcerations." J Am Dent Assoc 122 (1991): 75-7
  • Gerber D "Adverse reactions of piroxicam." Drug Intell Clin Pharm 21 (1987): 707-10
  • Linder JD, Klaus E, Monkemuller KE, Davis JV, Wilcox CM "Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia." South Med J 93 (2000): 930-2
  • Singh G, Ramey DR, Morfeld D, Fries JF "Comparative toxicity of non-steroidal anti-inflammatory agents." Pharmacol Ther 62 (1994): 175-91
  • Peterson WL, Cryer B "COX-1-sparing NSAIDs - Is the enthusiasm justified?." JAMA 282 (1999): 1961-3
  • "Product Information. Indocin (indomethacin)." Merck & Co, Inc, West Point, PA.
  • "Product Information. Celebrex (celecoxib)." Searle, Chicago, IL.
  • Langman MJ, Jensen DM, Watson DJ, et al. "Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs." JAMA 282 (1999): 1929-33
  • Talbot R, Rees H "Perforated duodenal ulcer on diflunisal (Dolobid) ." Br Med J 2 (1978): 1229
  • Day TK "Intestinal perforation associated with osmotic slow release indomethacin capsules." Br Med J 287 (1983): 1671-2
Ketoprofen Capsules

非专利名称: ketoprofen

品牌: Oruvail, Orudis, Actron, Orudis KT

同义词: Ketoprofen

Ketoprofen Capsules是什么？
其他的药物 删除
公认药物相互作用的清单
DiseDoc 和平
与食物，生活方式相互作用
  1. Ketoprofen Capsules
药物互相作用
  1. Ketoprofen Capsules
我们使用Cookie来优化网站性能。通过继续浏览这个网站,你同意使用Cookie。 同意